- Yale Cancer CenterYale New Haven Hospital20 York Street, Ste North Pavilion 7New Haven, CT 06510
Iris Isufi, MD
Biography
Iris Isufi, MD, is a hematologist who specializes in treating patients with lymphoma, multiple myeloma, and leukemia. Dr. Isufi provides care through treatments involving cellular therapy, which include CAR T-cell therapy and stem cell transplants. She is co-director of the CAR T-Cell Therapy Program for adults.
“Cell therapies like CAR T-cell therapy are promising for diseases that haven’t responded to multiple types of treatment,” Dr. Isufi says. “It’s a recent development, but one that students in medical school are already learning about, and that’s very exciting.”
The potential benefit of CAR T-cell therapy matters especially to Dr. Isufi, who grew up in Albania and sometimes accompanied her mother, a physician, on rounds at the hospital. “I saw challenges they [the doctors] were facing in trying to help people. Their determination inspired me when I was young to become a physician,” Dr. Isufi says.
As she visits her cancer patients today, Dr. Isufi spends time getting to know each one so that she can provide reassurance for each person’s unique situation. “I tell them we are in this together and that I’ll do my best to help them get through it all—beginning to end,” she says. Dr. Isufi continues to check in on patients who have been in remission for many years after receiving their treatment.
“My patients are very grateful, brave, and courageous, and this inspires me,” she says.
Dr. Isufi is an assistant professor of hematology at Yale School of Medicine, where she also runs clinical trials in patients with lymphoma.
Titles
- Associate Professor of Medicine (Hematology)
- Co-Director Adult CAR T-Cell Therapy Program, Hematology
- Co-Leader, Cellular Therapy Clinical Research Team, Yale Cancer Center
- Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center
Education & Training
- FellowshipYale University School of Medicine (2011)
- ResidencyAlbert Einstein College of Medicine/Montefiore Medical Center (2007)
- MDState University of New York at Stony Brook (2004)
- BAThe College of Saint Rose, Albany, NY, 2000, Biology (2000)
Languages Spoken
- English
- Italiano (Italian)
- Español (Spanish)
Additional Information
- ASCO/AACR Methods in Clinical Cancer Research Workshop Fellow, Vail, CO: AACR (2008)
- Outstanding House Officer in Internal Medicine Award: Albert Einstein College of Medicine/Montefiore Medical Center (2007)
- The Kijeon Yoo Award for Determination in Pursuit of a Medical Education: Stony Brook University School of Medicine (2004)
- Medical School Merit-Based Scholarship: Stony Brook University School of Medicine (2004)
- Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.
- Dahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s462-s463. DOI: 10.1016/s2152-2650(24)01497-6.
- Dahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s212. DOI: 10.1016/s2152-2650(24)00792-4.
- Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.
- Weisel K, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Karlin L. P-096 Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s97-s98. DOI: 10.1016/s2152-2650(24)01999-2.
- Gehrie E, Young P, Basavaraju S, Bracey A, P. A, Culler L, Dunbar N, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey C, Kaufman R, Snyder E. Addressing platelet insecurity – A national call to action. Transfusion 2024, 64: 2001-2013. PMID: 39133194, DOI: 10.1111/trf.17987.
- Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.
- Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.
- Ghobadi A, Jacobson C, McGuirk J, Shah N, Rossi J, Buchholz T, Bachier-Rodriguez L, Baird J, Diefenbach C, Farooq U, Hernandez-Ilizaliturri F, Isufi I, Patel K, Neelapu S, Sauter C, Spiegel J, Tees M, Timmerman J, Laport G, Frank M. Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy. Journal Of Clinical Oncology 2024, 42: tps7085-tps7085. DOI: 10.1200/jco.2024.42.16_suppl.tps7085.
- Palomba M, Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Transplantation And Cellular Therapy 2024, 30: s40-s41. DOI: 10.1016/j.jtct.2023.12.071.
- Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan F, Dholaria B, Maakaron J, Sandoval-Sus J, Mishra R, Saha A, Annunzio K, Bhaskar S, Sumransub N, Fijalka A, Ivanov S, Lin Y, Kharfan-Dabaja M. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation 2023, 59: 211-216. PMID: 37973893, DOI: 10.1038/s41409-023-02148-4.
- Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.
- Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Palomba M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Blood 2023, 142: 104. DOI: 10.1182/blood-2023-180242.
- Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Karlin L, Weisel K. Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy. Blood 2023, 142: 1063. DOI: 10.1182/blood-2023-178798.
- Desai S, Sumransub N, Evans R, Watkins M, Karmali R, Goyal G, Hughes M, Khurana A, Hernandez-Ilizaliturri F, Zurko J, Hassan A, Hatic H, Nizamuddin I, Evens A, Anampa-Guzmán A, Lin Y, Isufi I, Hamadani M, Rajguru S, Lall N, Tun A, Hill B, Stephens D, Caimi P, Ermann D, Kahl B, Landsburg D, Nowakowski G. Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy. Blood 2023, 142: 308. DOI: 10.1182/blood-2023-183001.
- Bair S, Narkhede M, Frosch Z, Chong E, Ermann D, Isufi I, Awan F, Chavez J, Bosma G, Abbott D. Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy. Blood 2023, 142: 68. DOI: 10.1182/blood-2023-187113.
- Verma A, Liburd S, Tobias Z, Isufi I, Pober J, Xu M. Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype. Blood 2023, 142: 2075. DOI: 10.1182/blood-2023-184963.
- Grommes C, Tun H, Rosenthal A, Lunning M, Ramchandren R, Regales L, Zhao W, Lane M, Wang C, von Roemeling R, Isufi I, Leslie L, Nowakowski G. Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies. Blood 2023, 142: 4497. DOI: 10.1182/blood-2023-189746.
- Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, JH T, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leukemia & Lymphoma 2021, 63: 821-833. PMID: 34865586, DOI: 10.1080/10428194.2021.2010057.
- Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, Isufi I, Azar MM. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal Of Infection And Chemotherapy 2021, 27: 1700-1705. PMID: 34389223, DOI: 10.1016/j.jiac.2021.08.005.
- Perreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. American Journal Of Health-System Pharmacy 2021, 78: 1112-1117. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.
- Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.
- Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.
- Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
- Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.
- Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.
- Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.
- Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.
- Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
- Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.
- Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.
- Saif MW, Isufi I, Peccerillo J, Syrigos KN. Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma. Gastroenterology Research And Practice 2011, 2011: 616080. PMID: 21687621, PMCID: PMC3113260, DOI: 10.1155/2011/616080.
- Lansigan F, Isufi I, Tagoe CE. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Rheumatology 2010, 50: 824-829. PMID: 21149242, DOI: 10.1093/rheumatology/keq395.
- Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Research 2010, 30: 2927-33. PMID: 20683034.
- Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, Pahanish P, Verma A. Transforming Growth Factor- Signaling in Normal and Malignant Hematopoiesis. Journal Of Interferon & Cytokine Research 2007, 27: 543-552. PMID: 17651015, DOI: 10.1089/jir.2007.0009.
- Yale Cancer CenterYale New Haven Hospital20 York Street, Ste North Pavilion 7New Haven, CT 06510
Biography
Iris Isufi, MD, is a hematologist who specializes in treating patients with lymphoma, multiple myeloma, and leukemia. Dr. Isufi provides care through treatments involving cellular therapy, which include CAR T-cell therapy and stem cell transplants. She is co-director of the CAR T-Cell Therapy Program for adults.
“Cell therapies like CAR T-cell therapy are promising for diseases that haven’t responded to multiple types of treatment,” Dr. Isufi says. “It’s a recent development, but one that students in medical school are already learning about, and that’s very exciting.”
The potential benefit of CAR T-cell therapy matters especially to Dr. Isufi, who grew up in Albania and sometimes accompanied her mother, a physician, on rounds at the hospital. “I saw challenges they [the doctors] were facing in trying to help people. Their determination inspired me when I was young to become a physician,” Dr. Isufi says.
As she visits her cancer patients today, Dr. Isufi spends time getting to know each one so that she can provide reassurance for each person’s unique situation. “I tell them we are in this together and that I’ll do my best to help them get through it all—beginning to end,” she says. Dr. Isufi continues to check in on patients who have been in remission for many years after receiving their treatment.
“My patients are very grateful, brave, and courageous, and this inspires me,” she says.
Dr. Isufi is an assistant professor of hematology at Yale School of Medicine, where she also runs clinical trials in patients with lymphoma.
Titles
- Associate Professor of Medicine (Hematology)
- Co-Director Adult CAR T-Cell Therapy Program, Hematology
- Co-Leader, Cellular Therapy Clinical Research Team, Yale Cancer Center
- Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center
Education & Training
- FellowshipYale University School of Medicine (2011)
- ResidencyAlbert Einstein College of Medicine/Montefiore Medical Center (2007)
- MDState University of New York at Stony Brook (2004)
- BAThe College of Saint Rose, Albany, NY, 2000, Biology (2000)
Languages Spoken
- English
- Italiano (Italian)
- Español (Spanish)
Additional Information
- ASCO/AACR Methods in Clinical Cancer Research Workshop Fellow, Vail, CO: AACR (2008)
- Outstanding House Officer in Internal Medicine Award: Albert Einstein College of Medicine/Montefiore Medical Center (2007)
- The Kijeon Yoo Award for Determination in Pursuit of a Medical Education: Stony Brook University School of Medicine (2004)
- Medical School Merit-Based Scholarship: Stony Brook University School of Medicine (2004)
- Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.
- Dahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s462-s463. DOI: 10.1016/s2152-2650(24)01497-6.
- Dahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s212. DOI: 10.1016/s2152-2650(24)00792-4.
- Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.
- Weisel K, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Karlin L. P-096 Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s97-s98. DOI: 10.1016/s2152-2650(24)01999-2.
- Gehrie E, Young P, Basavaraju S, Bracey A, P. A, Culler L, Dunbar N, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey C, Kaufman R, Snyder E. Addressing platelet insecurity – A national call to action. Transfusion 2024, 64: 2001-2013. PMID: 39133194, DOI: 10.1111/trf.17987.
- Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.
- Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.
- Ghobadi A, Jacobson C, McGuirk J, Shah N, Rossi J, Buchholz T, Bachier-Rodriguez L, Baird J, Diefenbach C, Farooq U, Hernandez-Ilizaliturri F, Isufi I, Patel K, Neelapu S, Sauter C, Spiegel J, Tees M, Timmerman J, Laport G, Frank M. Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy. Journal Of Clinical Oncology 2024, 42: tps7085-tps7085. DOI: 10.1200/jco.2024.42.16_suppl.tps7085.
- Palomba M, Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Transplantation And Cellular Therapy 2024, 30: s40-s41. DOI: 10.1016/j.jtct.2023.12.071.
- Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan F, Dholaria B, Maakaron J, Sandoval-Sus J, Mishra R, Saha A, Annunzio K, Bhaskar S, Sumransub N, Fijalka A, Ivanov S, Lin Y, Kharfan-Dabaja M. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation 2023, 59: 211-216. PMID: 37973893, DOI: 10.1038/s41409-023-02148-4.
- Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.
- Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Palomba M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Blood 2023, 142: 104. DOI: 10.1182/blood-2023-180242.
- Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Karlin L, Weisel K. Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy. Blood 2023, 142: 1063. DOI: 10.1182/blood-2023-178798.
- Desai S, Sumransub N, Evans R, Watkins M, Karmali R, Goyal G, Hughes M, Khurana A, Hernandez-Ilizaliturri F, Zurko J, Hassan A, Hatic H, Nizamuddin I, Evens A, Anampa-Guzmán A, Lin Y, Isufi I, Hamadani M, Rajguru S, Lall N, Tun A, Hill B, Stephens D, Caimi P, Ermann D, Kahl B, Landsburg D, Nowakowski G. Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy. Blood 2023, 142: 308. DOI: 10.1182/blood-2023-183001.
- Bair S, Narkhede M, Frosch Z, Chong E, Ermann D, Isufi I, Awan F, Chavez J, Bosma G, Abbott D. Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy. Blood 2023, 142: 68. DOI: 10.1182/blood-2023-187113.
- Verma A, Liburd S, Tobias Z, Isufi I, Pober J, Xu M. Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype. Blood 2023, 142: 2075. DOI: 10.1182/blood-2023-184963.
- Grommes C, Tun H, Rosenthal A, Lunning M, Ramchandren R, Regales L, Zhao W, Lane M, Wang C, von Roemeling R, Isufi I, Leslie L, Nowakowski G. Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies. Blood 2023, 142: 4497. DOI: 10.1182/blood-2023-189746.
- Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, JH T, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leukemia & Lymphoma 2021, 63: 821-833. PMID: 34865586, DOI: 10.1080/10428194.2021.2010057.
- Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, Isufi I, Azar MM. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal Of Infection And Chemotherapy 2021, 27: 1700-1705. PMID: 34389223, DOI: 10.1016/j.jiac.2021.08.005.
- Perreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. American Journal Of Health-System Pharmacy 2021, 78: 1112-1117. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.
- Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.
- Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.
- Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
- Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.
- Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.
- Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.
- Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.
- Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
- Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.
- Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.
- Saif MW, Isufi I, Peccerillo J, Syrigos KN. Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma. Gastroenterology Research And Practice 2011, 2011: 616080. PMID: 21687621, PMCID: PMC3113260, DOI: 10.1155/2011/616080.
- Lansigan F, Isufi I, Tagoe CE. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Rheumatology 2010, 50: 824-829. PMID: 21149242, DOI: 10.1093/rheumatology/keq395.
- Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Research 2010, 30: 2927-33. PMID: 20683034.
- Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, Pahanish P, Verma A. Transforming Growth Factor- Signaling in Normal and Malignant Hematopoiesis. Journal Of Interferon & Cytokine Research 2007, 27: 543-552. PMID: 17651015, DOI: 10.1089/jir.2007.0009.
- Yale Cancer CenterYale New Haven Hospital20 York Street, Ste North Pavilion 7New Haven, CT 06510
- Yale Cancer CenterYale New Haven Hospital20 York Street, Ste North Pavilion 7New Haven, CT 06510